ASSOCIATION FOR ACCESSIBLE MEDICINES

Lobbying for ASSOCIATION FOR ACCESSIBLE MEDICINES

Filing 3rd Quarter - Report

Reporting period

3rd Quarter 2025

July 1 - Sep 30 · Posted Oct 20, 2025

Expenses

$640,000.00

What this organization spent lobbying with its own staff. Reported using A: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

District of Columbia

Official filing document

Lobbyists on this filing 1

MARK RATNER New on this filing

Previously held: Covered Positions Continued: Policy Coordinator-House Energy & Commerce Committee Energy Subcommittee (Rep. Fred Upton); Policy Coordinator-House Energy & Commerce Committee Energy (Rep. Fred Upton); Sr. LA/LA-Rep. Fred Upton; LA-Rep. Joe Schwarz

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 14

Centers For Medicare and Medicaid Services (CMS)
Commerce, Dept of (DOC)
Congressional Budget Office (CBO)
Federal Trade Commission (FTC)
Food & Drug Administration (FDA)
Health & Human Services, Dept of (HHS)
HOUSE OF REPRESENTATIVES
Justice, Dept of (DOJ)
Natl Economic Council (NEC)
Office of Management & Budget (OMB)
SENATE
U.S. Customs & Border Protection
U.S. Trade Representative (USTR)
White House Office

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 27

HR 1843
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
S 1302
Increasing Transparency in Generic Drug Applications Act
S 2296
National Defense Authorization Act for Fiscal Year 2026
HR 1396
PILLS Act
S 1891
PILLS Act
HR 5526
Biosimilar Red Tape Elimination Act
S 1954
Biosimilar Red Tape Elimination Act
HR 1051
To amend the Federal Food, Drug, and Cosmetic Act to allow for the approval of an abbreviated new drug application subm…
HR 3955
RAPID Reserve Act
S 2062
RAPID Reserve Act
HR 4191
MAPS Act
S 1784
MAPS Act
HR 4132
Prescription Information Modernization Act of 2025
S 2027
Prescription Information Modernization Act of 2025
S 1414
Expedited Access to Biosimilars Act
HR 3160
PREVAIL Act
S 1553
PREVAIL Act
HR 3152
Patent Eligibility Restoration Act of 2025
S 1546
Patent Eligibility Restoration Act of 2025
HR 3269
ETHIC Act
S 2276
ETHIC Act
S 1041
Affordable Prescriptions for Patients Act
S 1096
Preserve Access to Affordable Generics and Biosimilars Act
S 43
Skinny Labels, Big Savings Act
S 1040
Drug Competition Enhancement Act
HR 4570
Interagency Patent Coordination and Improvement Act of 2025
S 1097
Interagency Patent Coordination and Improvement Act of 2025

Lobbying activity 4

Pharmacy

Prescription Drug Costs. H.R.1843: To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications. S.1302: Increasing Transparency in Generic Drug Applications Act. Generic Drug Reporting Requirement Language in the Senate NDAA, S.2296 - National Defense Authorization Act for Fiscal Year 2026. H.R.1396/S.1891: Producing Incentives for Long-term Production of Lifesaving Supply of Medicine (PILLS) Act. Drug Shortages. H.R.5526/S.1954: Biosimilar Red Tape Elimination Act (BRTEA). H.R.1051: To amend the Federal Food, Drug, and Cosmetic Act to allow for the approval of an abbreviated new drug application submitted by a subsequent applicant in the case of a failure by a first applicant to commence commercial marketing within a certain period, and for other purposes. American Relief Act, 2025 (PL. No: 118-158) as it relates to Patent Thickets and Q1/Q2. H.R.3955/S.2062: RAPID Reserve Act. H.R.4191/S.1784: Mapping Americas Pharmaceutical Supply (MAPS) Act. H.R.4132/S.2027: Prescription Information Modernization Act of 2025. Establishment Inspection Reports. S.1414/H.R._: Expedited Access to Biosimilars Act.

Medicare/Medicaid

Medicare Part D Reform. Medicaid Rebate Penalty. Medicare/Medicaid Inflation Penalties. Medicare Conditions of Participation.

H.R.3160/S.1553: Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act. H.R.3152/S.1546: Patent Eligibility Restoration Act of 2025. H.R.3269/S.2276: Eliminating Thickets to Increase Competition (ETHIC) Act. S.1041: Affordable Prescriptions for Patients Act. S.1096: Preserve Access to Affordable Generics and Biosimilars Act. S.43: Skinny Labels, Big Savings Act. S.1040: Drug Competition Enhancement Act. H.R.4570/S.1097: Interagency Patent Coordination and Improvement Act of 2025.

Trade (domestic/foreign)

General Trade Issues. Drug Supply Chain. Country of Origin Labeling. Tariffs on Generic Medicines. Quotas on Generic Medicines. Increasing Domestic Production of Generics and Biosimilars.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.